Clinical trial · Observational
Patient Satisfaction and Quality of Life Impact - PecFent®
A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)
NCT01693328CI-TRIAL-00013467QualipecunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breakthrough Cancer Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PecFent® (fentanyl) nasal spray | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PecFent®
- interventionNames
- Drug: PecFent® (fentanyl) nasal spray
Primary outcomes (1)
- measure
- Satisfaction
- timeFrame
- Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7
- description
- Satisfaction will be assessed using a 4-point Likert scale.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (aged ≥18 years) with cancer * Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain
References
Publications (0)
Data not yet available
No reference posted for this study.